Physician profile
George Chu
NPI 1467562678
$4,695.95
in general payments reported to CMS, 2019-2025
28 companies · $630 in 2025
The $630 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $451 · 2021: $634 · 2022: $526 · 2023: $699 · 2024: $695 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.10 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $807.97 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Tosoh Bioscience, INC. | $526.00 | 2019 | |
| Amgen INC. | $366.47 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.21 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $238.90 | 2019-2022 | |
| Abbvie INC. | $237.43 | 2019-2023 | Ubrelvy |
| Abbott Laboratories | $141.15 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $136.83 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $130.55 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.39 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $69.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.63 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $58.90 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $53.88 | 2021-2024 | Nexletol |
| Glaxosmithkline, LLC. | $47.22 | 2019-2023 | Arexvy |
| Eisai INC. | $43.11 | 2020 | |
| Bausch Health US, LLC | $36.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.56 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $31.89 | 2025 | |
| Edwards Lifesciences Corporation | $30.26 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $26.66 | 2021-2022 | |
| Corcept Therapeutics | $22.14 | 2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $19.31 | 2025 | Givlaari |
| Axsome Therapeutics, INC. | $16.40 | 2025 | Auvelity |
| Genentech USA, INC. | $16.14 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.